Sreepriya Prasannan

A detailed step-by-step LinkedIn guide for Regulatory Affairs Specialists, Quality Assurance professionals, Pharmacovigilance Officers, CMC Scientists, and all pharmaceutical compliance professionals. Learn exactly how to frame your regulatory expertise on LinkedIn to attract the right roles, visibility, and recognition - without exposing proprietary submissions or confidential regulatory strategy.

The United States has formally launched a trade investigation under Section 301 into Germany’s drug reimbursement practices, citing concerns that domestic price controls unfairly burden American innovation.

A detailed global report analyzing major pharmaceutical and biotech layoffs across the US, EU, and India from 2025 to 2026, including strategic shifts by enGene, Takeda, Bayer, and BioNTech.

Drugmakers such as Eli Lilly, Pfizer, AstraZeneca, and Roche have collectively announced approximately $500 billion in U.S. investments aimed at strengthening infrastructure and reducing supply-chain vulnerabilities.

An in-depth analysis of how US Most Favored Nation (MFN) drug pricing proposals and the Inflation Reduction Act (IRA) are forcing pharmaceutical companies to restructure indication sequencing, ex-US launches, and global supply chains.

Japanese pharmaceutical company Eisai announces a £48 million investment at its Hatfield, UK site to establish advanced cold-chain supply and packaging capabilities, supported by the Life Sciences Innovative Manufacturing Fund.

With the US-Iran peace deal signed and the Strait of Hormuz set to reopen, Ireland's pharmaceutical export sector stands to benefit from stabilized global energy tariffs, normalized maritime trade corridors, and renewed multinational capital inflows.

An expert analysis of the strategic shifts required in global drug development, indication sequencing, and launch timelines in response to proposed Most Favored Nation pricing and the Inflation Reduction Act.

A detailed analytical deep-dive into the Irish Government's 2026 updates to Critical Skills and General Employment Permit lists, reviewing quotas, key sectors, and the proposed changes to the 50:50 rule.

AbbVie is reportedly in advanced negotiations to acquire clinical-stage biotech Apogee Therapeutics for approximately $10.9 billion in cash, aiming to secure the promising long-acting eczema therapy zumilokibart.

Moroccan pharmaceutical group Laprophan finalizes its acquisition of a controlling stake in Swiss pharmaceutical firm Rivopharm, securing a strategic industrial base in Europe and expanding its global footprint.

Japanese biotech J-Pharma and Ireland-based Uniphar have received FDA alignment to bypass Phase II and advance nanvuranlat (JPH203) directly into a pivotal global Phase III study for second-line biliary tract cancer.